Genentech reveals positive results from cancer combo therapy trial

Genentech has reported positive findings from the Phase III IMbrave050 trial of Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) to treat patients with hepatocellular carcinoma (HCC), a type of adjuvant liver cancer.